Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical and genetic characterization of genital and inverse psoriasis as a distinct psoriasis endotype.

The Journal of investigative dermatology·2026

Same author

Amplification of pro-proliferative genes adjacent to the F3 gene in pancreatic adenocarcinoma is associated with worse outcomes.

Cell cycle (Georgetown, Tex.)·2026

Same author

<i>Letter:</i> Emergency Department Charges Associated With Contact Dermatitis in the USA: A Retrospective Analysis of 121,460 Visits.

Dermatitis : contact, atopic, occupational, drug·2026

Same author

Assessment of mental health disorders among patients with lichen simplex chronicus.

The British journal of dermatology·2026

Same author

T-cell receptor anti-CMV CDR3s from bone marrow samples are associated with a worse overall survival for recurrent acute myeloid leukemia.

Leukemia research reports·2026

Same author

Chemical Complementarities of Neuroblastoma Tumor-Resident TCR CDR3s and CMV Antigens are Associated with a Better Outcome.

Biochemical genetics·2026

Search research articles

Related Experiment Video

Updated: Jun 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Better Outcomes for Ovarian Cancer Associated With the Detection of Anti-EBV TCR CDR3s: Potential Relevance to

Nandini Goel¹, Madeline C Baker¹, Michael T Aboujaoude¹

¹Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.

American Journal of Reproductive Immunology (New York, N.Y. : 1989)

|January 17, 2025

Summary

Patients with Epstein-Barr virus (EBV)-specific T-cell receptor (TCR) complementarity domain region-3 (CDR3) sequences showed improved ovarian cancer survival. This suggests a potential role for EBV in ovarian cancer outcomes and immunotherapy.

Keywords:

Epstein–Barr virus TCR CDR3s disease‐specific survival ovarian cancer overall survival

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jun 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Area of Science:

Oncology
Immunology
Virology

Background:

Viral infections present challenges in understanding cancer etiology and comorbidities.
The role of specific antiviral immune responses in cancer progression and patient outcomes remains an area of active investigation.

Purpose of the Study:

To investigate the association between anti-viral T-cell receptor (TCR) complementarity domain region-3 (CDR3) sequences and clinical outcomes in ovarian cancer patients.
To explore the potential diagnostic and prognostic value of specific antiviral immune signatures in ovarian cancer.

Main Methods:

Isolation of TCR CDR3 sequences from ovarian cancer specimens.
Analysis of anti-viral CDR3 sequences, focusing on Epstein-Barr virus (EBV), cytomegalovirus, influenza A, and Sars-CoV-2.
Comparison of CDR3 sequence frequencies and patient outcomes, including overall and disease-specific survival.
Assessment of anti-EBV CDR3 frequencies in lymphoma patients to investigate potential misdiagnoses.

Main Results:

Patients with exact matches of anti-Epstein-Barr virus (EBV) CDR3 amino acid sequences demonstrated significantly better overall and disease-specific survival.
No improved outcomes were observed for anti-viral CDR3s targeting cytomegalovirus, influenza A, or Sars-CoV-2.
High frequencies of anti-EBV CDR3s were found in lymphoma patients, particularly diffuse large B-cell lymphoma, suggesting a potential link or misdiagnosis issue.

Conclusions:

Anti-EBV immune responses may hold significant prognostic value for ovarian cancer patients.
The findings raise important questions regarding the potential efficacy of anti-EBV immunotherapies in ovarian cancer.
Further research is warranted to elucidate the relationship between EBV infection and ovarian cancer, including potential cases of ovary-resident lymphoma.